A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Recruiting now · Not applicable

Conditions studied: NSCLC, Stage III, NSCLC, Stage IV

In brief

Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies. Anti-tumor synergism has been identified by combining ADT with anti-PD-1 immunotherapy for androgen-independent tumors. This study is to investigate the combination of Leuprorelin ADT and Sintilimab (anti-PD-1) therapy in patients with advanced lung cancer.

Key facts

Study ID

NCT06512207

Run by

Jinzhou Medical University

People needed

80

Starts

2023-12-03

Expected to finish

2026-06-01

Last updated by the study team

2025-09-09

Who can join

Age: 60 and older. Sex: male. Healthy volunteers: not accepted.

You may not qualify if…

• Exclusion of cases that do not meet the inclusion criteria

Where it is running

• The Third Oncology Ward, First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.